AU2004229464A1 - Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist - Google Patents

Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist Download PDF

Info

Publication number
AU2004229464A1
AU2004229464A1 AU2004229464A AU2004229464A AU2004229464A1 AU 2004229464 A1 AU2004229464 A1 AU 2004229464A1 AU 2004229464 A AU2004229464 A AU 2004229464A AU 2004229464 A AU2004229464 A AU 2004229464A AU 2004229464 A1 AU2004229464 A1 AU 2004229464A1
Authority
AU
Australia
Prior art keywords
formulation
opioid antagonist
peripheral opioid
patient
peripheral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004229464A
Other languages
English (en)
Inventor
Thomas A. Boyd
Paul J. Maddon
Suketu P. Sanghvi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Progenics Pharmaceuticals Inc
Original Assignee
Progenics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharmaceuticals Inc filed Critical Progenics Pharmaceuticals Inc
Publication of AU2004229464A1 publication Critical patent/AU2004229464A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2004229464A 2003-04-08 2004-04-08 Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist Abandoned AU2004229464A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46158503P 2003-04-08 2003-04-08
US60/461,585 2003-04-08
PCT/US2004/010998 WO2004091665A1 (en) 2003-04-08 2004-04-08 Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist

Publications (1)

Publication Number Publication Date
AU2004229464A1 true AU2004229464A1 (en) 2004-10-28

Family

ID=33299838

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004229464A Abandoned AU2004229464A1 (en) 2003-04-08 2004-04-08 Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist

Country Status (10)

Country Link
US (1) US20040259899A1 (enExample)
EP (1) EP1638607A1 (enExample)
JP (1) JP2006522819A (enExample)
CN (1) CN1767855A (enExample)
AU (1) AU2004229464A1 (enExample)
BR (1) BRPI0409125A (enExample)
CA (1) CA2521420A1 (enExample)
MX (1) MXPA05010821A (enExample)
RU (1) RU2005134364A (enExample)
WO (1) WO2004091665A1 (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
BRPI0409133B8 (pt) 2003-04-08 2021-05-25 Progenics Pharm Inc preparações farmacêuticas estavéis compreendendo metilnaltrexona
EP1617846A1 (en) * 2003-04-08 2006-01-25 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
SG173326A1 (en) * 2004-06-04 2011-08-29 Camurus Ab Liquid depot formulations
EP1845989A1 (en) * 2005-01-20 2007-10-24 Progenics Pharmaceuticals, Inc. Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
BRPI0608818A2 (pt) 2005-03-07 2010-01-26 Univ Chicago uso de antagonista opióides para atenuação de proliferação e migração de células endoteliais
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
EP3827747A1 (en) 2005-04-28 2021-06-02 Otsuka Pharmaceutical Co., Ltd. Pharma-informatics system
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
DE102006044694A1 (de) * 2006-09-22 2008-03-27 Krewel Meuselbach Gmbh Perorale feste Schmerzmittelzubereitung
JP5916277B2 (ja) 2006-10-25 2016-05-11 プロテウス デジタル ヘルス， インコーポレイテッド 摂取可能な制御活性化識別子
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
CA2682125C (en) 2007-03-29 2015-06-16 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
EP2134718A2 (en) 2007-03-29 2009-12-23 Progenics Pharmaceuticals, Inc. Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
MX2010001629A (es) 2007-08-10 2010-08-09 Alessandro Sannino Hidrogeles de polimero y metodos de preparacion de los mismos.
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
CA2713568C (en) 2008-02-06 2016-09-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
EP2306829B1 (en) * 2008-07-01 2017-01-04 University of Chicago Particles containing a peripheral opioid receptor antagonist
SG195535A1 (en) 2008-07-08 2013-12-30 Proteus Digital Health Inc Ingestible event marker data framework
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
TWI449685B (zh) * 2008-12-10 2014-08-21 Theravance Inc ３－羧基丙基－胺基四氫化萘化合物之結晶型
BR122013009559A2 (pt) 2009-04-28 2019-08-06 Proteus Digital Health, Inc. Marcadores de evento de ingerível altamente confiável e métodos para usar os mesmos
US20100317682A1 (en) * 2009-06-11 2010-12-16 Richard Fuisz Single Dosage Unit Including Opioid and Methylnaltrexone or Methylnaltrexone Salt
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
TWI517050B (zh) 2009-11-04 2016-01-11 普羅托斯數位健康公司 供應鏈管理之系統
AU2016200133B2 (en) * 2010-03-11 2017-09-07 Wyeth Llc Oral formulations and lipophilic salts of methylnaltrexone
KR101982482B1 (ko) * 2010-03-11 2019-05-27 와이어쓰 엘엘씨 메틸날트렉손의 경구 제형 및 친유성 염
AU2013203559B2 (en) * 2010-03-11 2015-12-03 Wyeth Llc Oral formulations and lipophilic salts of methylnaltrexone
RU2012143791A (ru) 2010-04-07 2014-05-20 Проутьюс Диджитал Хэлс, Инк. Миниатюрное проглатываемое устройство
JP5840201B2 (ja) 2010-05-10 2016-01-06 ユーロ−セルティーク エス．エイ． 活性剤を負荷した顆粒と追加の活性剤の組合せ
NZ700732A (en) 2010-05-10 2015-08-28 Euro Celtique Sa Pharmaceutical compositions comprising hydromorphone and naloxone
ES2642788T3 (es) 2010-05-10 2017-11-20 Euro-Celtique S.A. Fabricación de gránulos sin principio activo y de comprimidos que comprenden los mismos
EP2632578A4 (en) * 2010-10-29 2014-12-03 Msd Consumer Care Inc CONCENTRATED THERAPEUTIC SOLUTION
JP2014504902A (ja) 2010-11-22 2014-02-27 プロテウス デジタル ヘルス， インコーポレイテッド 医薬品を有する摂取可能なデバイス
AU2011342368B2 (en) * 2010-12-13 2016-11-17 Rite-Prep Pty Ltd Gastric and colonic formulations and methods for making and using them
CN102641496A (zh) 2011-02-16 2012-08-22 辛绍祺 高分子聚合物的新用途及其组成物
PL395069A1 (pl) * 2011-05-31 2012-12-03 Warszawski Uniwersytet Medyczny Przeciwbólowa kompozycja farmaceutyczna do podawania doustnego
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US20180326069A1 (en) * 2011-10-24 2018-11-15 Bayer Healthcare Llc Therapeutic solution concentrate
PL2877155T3 (pl) 2012-07-26 2021-05-17 Camurus Ab Formulacje opioidowe
LT2877155T (lt) 2012-07-26 2021-02-25 Camurus Ab Opioidų vaisto formos
US10166219B2 (en) 2012-07-27 2019-01-01 Redhill Bipharma Ltd. Formulations and methods of manufacturing formulations for use in colonic evacuation
TWI659994B (zh) 2013-01-29 2019-05-21 美商普羅托斯數位健康公司 高度可膨脹之聚合型薄膜及包含彼之組成物
US10175376B2 (en) 2013-03-15 2019-01-08 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
WO2014197402A1 (en) 2013-06-04 2014-12-11 Proteus Digital Health, Inc. System, apparatus and methods for data collection and assessing outcomes
US20160151296A1 (en) * 2013-05-22 2016-06-02 Empire Technology Development Llc Long delayed release laxative
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
EP3068397A1 (en) 2013-11-13 2016-09-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US20160256451A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Dosage of naloxone
WO2016193456A2 (en) * 2015-06-03 2016-12-08 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
EP3448365A4 (en) * 2016-04-25 2019-12-25 Gelesis, LLC. METHOD FOR TREATING CONSTRUCTION
WO2018018034A1 (en) 2016-07-22 2018-01-25 Proteus Digital Health, Inc. Electromagnetic sensing and detection of ingestible event markers
JP2019535377A (ja) 2016-10-26 2019-12-12 プロテウス デジタル ヘルス， インコーポレイテッド 摂取可能なイベントマーカを有するカプセルの製造方法
MX2021013488A (es) * 2019-05-07 2021-12-10 Bausch Health Ireland Ltd Formulaciones liquidas de dosis oral de metilnaltrexona.
CN115040512B (zh) * 2022-07-28 2023-06-20 苏州中化药品工业有限公司 一种药物组合物及其制备方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
JPS5535031A (en) * 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
US4311833A (en) * 1979-03-06 1982-01-19 Daicel Chemical Industries Ltd. Process for preparing ethylcarboxymethylcellulose
US4322426A (en) * 1980-04-28 1982-03-30 E. I. Du Pont De Nemours And Company 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4987136A (en) * 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
US4457907A (en) * 1982-08-05 1984-07-03 Clear Lake Development Group Composition and method for protecting a therapeutic drug
US4518433A (en) * 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4462839A (en) * 1983-06-16 1984-07-31 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4556552A (en) * 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
EP0143949B1 (en) * 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US5266574A (en) * 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
JPS6229515A (ja) * 1985-07-30 1987-02-07 Shinjiro Tsuji 硬カプセル剤のフイルムコ−テイング方法
US4861781A (en) * 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4719215A (en) * 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US5597564A (en) * 1986-08-28 1997-01-28 Enzacor Properties Limited Method of administering a microgranular preparation to the intestinal region of animals
AU604052B2 (en) * 1986-08-28 1990-12-06 Enzacor Properties Limited Animal growth promotant
US4888346A (en) * 1986-10-07 1989-12-19 Bernard Bihari Method for the treatment of persons infected with HTLV-III (AIDS) virus
US4857833A (en) * 1987-08-27 1989-08-15 Teradyne, Inc. Diagnosis of faults on circuit board
US5102887A (en) * 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
JPH04230625A (ja) * 1990-12-27 1992-08-19 Standard Chem & Pharmaceut Corp Ltd 噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5270328A (en) * 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
CA2110899C (en) * 1991-06-21 2006-08-08 Jacob G. Michael Orally administrable therapeutic proteins and method of making
US5614219A (en) * 1991-12-05 1997-03-25 Alfatec-Pharma Gmbh Oral administration form for peptide pharmaceutical substances, in particular insulin
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
ES2095001T5 (es) * 1992-12-22 2001-03-16 Univ Cincinnati Una composicion terapeutica administrable oralmente y su metodo de obtencion.
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5391372A (en) * 1993-06-28 1995-02-21 Campbell; Elizabeth Methods of treating colic and founder in horses
GB2281205A (en) * 1993-08-24 1995-03-01 Euro Celtique Sa Oral opioid analgesic
DE69503126T2 (de) * 1994-05-05 1998-11-12 Beckman Instruments Inc Repetitive oligonukleotide matrix
IT1269826B (it) * 1994-05-24 1997-04-15 Paolo Minoia Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US5614222A (en) * 1994-10-25 1997-03-25 Kaplan; Milton R. Stable aqueous drug suspensions and methods for preparation thereof
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
US6025154A (en) * 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US5804595A (en) * 1995-12-05 1998-09-08 Regents Of The University Of Minnesota Kappa opioid receptor agonists
PT914097E (pt) * 1996-03-12 2002-06-28 Alza Corp Composicao e forma de dosagem compreendendo antagonista de opioide
DE19651551C2 (de) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US6353004B1 (en) * 1997-07-14 2002-03-05 Adolor Coporation Peripherally acting anti-pruritic opiates
US5972954A (en) * 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6559158B1 (en) * 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
CA2380524A1 (en) * 1999-08-25 2001-03-01 Barrett R. Cooper Compositions and methods for treating opiate intolerance
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) * 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US6967075B2 (en) * 2000-04-07 2005-11-22 Schering Corporation HCV replicase complexes
US7534772B2 (en) * 2000-06-22 2009-05-19 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
EP1404323B1 (en) * 2001-06-05 2009-10-28 The University of Chicago Use of methylnaltrexone to treat immune suppression
PT2939696E (pt) * 2001-10-18 2016-06-17 Nektar Therapeutics Conjugados poliméricos de antagonistas de opióides
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
US6986901B2 (en) * 2002-07-15 2006-01-17 Warner-Lambert Company Llc Gastrointestinal compositions
BRPI0409133B8 (pt) * 2003-04-08 2021-05-25 Progenics Pharm Inc preparações farmacêuticas estavéis compreendendo metilnaltrexona
EP1617846A1 (en) * 2003-04-08 2006-01-25 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
US7066888B2 (en) * 2003-10-29 2006-06-27 Allez Physionix Ltd Method and apparatus for determining an ultrasound fluid flow centerline
EP1845989A1 (en) * 2005-01-20 2007-10-24 Progenics Pharmaceuticals, Inc. Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS

Also Published As

Publication number Publication date
US20040259899A1 (en) 2004-12-23
CA2521420A1 (en) 2004-10-28
CN1767855A (zh) 2006-05-03
RU2005134364A (ru) 2006-06-10
WO2004091665A1 (en) 2004-10-28
JP2006522819A (ja) 2006-10-05
MXPA05010821A (es) 2006-03-30
EP1638607A1 (en) 2006-03-29
BRPI0409125A (pt) 2006-03-28

Similar Documents

Publication Publication Date Title
US20040259899A1 (en) Combination therapy for constipation
RU2373936C2 (ru) Применение метилналтрексона для лечения синдрома раздраженного кишечника
EP2448406B1 (en) Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
ES2609695T3 (es) Comprimidos de oxicodona resistentes al aplastamiento destinados a evitar el uso incorrecto involuntario y la desviación ilícita de uso
US6277412B1 (en) Pellet-type formulation intended for treating the intestinal tract
US10624887B2 (en) Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14,-diol
KR101858797B1 (ko) 히드로모르폰 및 날록손을 포함하는 제약 조성물
WO2008089260A2 (en) Combined administration of benzonatate and guaifenesin
WO2000006128A1 (fr) Preparation capable de liberer un medicament au niveau d'un site cible dans l'intestin
EP1172100A1 (en) Oral solid pharmaceutical formulations with ph-dependent multiphasic release
KR20090014392A (ko) 결장 흡수용 페닐에프린 약제학적 제형 및 조성물
PL208080B1 (pl) Postacie dawkowane zawierające 5,8,14-triazatetracyklo[10.3.1.0²’¹¹.0⁴’⁹]heksadeka-2(11),3,5,7,9-pentaen i zastosowanie 5,8,14-triazatetracyklo[10.3.1.0²’¹¹.0⁴’⁹] heksadeka-2(11),3,5,7,9-pentaenu
CN102143740A (zh) 阿片类拮抗剂治疗尿潴留的用途
EP1916995B2 (en) Ph-controlled pulsatile delivery system, methods for preparation and use thereof
JP2015509539A (ja) メラサミンの放出制御固形製剤
WO2007037259A1 (ja) 生体内での崩壊性を向上させたパルス製剤
CN101797253B (zh) 一种岩白菜素、盐酸西替利嗪复方口服剂型
EP4595954A1 (en) Compositions and methods for treating bile acid malabsorption
HK1098954B (en) Solid pharmaceutical preparation containing sparingly water-soluble drug
NZ565272A (en) pH-controlled pulsatile delivery system, methods for preparation and use thereof
HK1120736A (en) Pulse preparation having improved disintegration properties in vivo

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application